Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
NCT06173505
Recruiting
The purpose of this study is to identify the recommended dose of vudalimab to be used in combination with chemotherapy (Part 1) and to evaluate the efficacy and safety of vudalimab plus standard of care chemotherapy relative to pembrolizumab plus chemotherapy (Part 2) as first-line treatment in patients with nonsquamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: Consultants in Medical Oncology and Hematology, P.C., Broomall, Pennsylvania
Conditions: Nonsquamous Non-small Cell Lung Cancer
Register for Updates
Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).
NCT05957042
Recruiting
To find out if contrast enhanced ultrasound (CEUS) can be used to determine if patients receiving combined ICI therapy for triple negative breast cancer (TNBC) are responding to treatment earlier than standard of care MR or CT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: Penn State Health College of Medicine, Hershey, Pennsylvania
Conditions: Breast Cancer, Contrast Enhanced Ultrasound
Register for Updates
Electrical Stimulation for the Treatment of Glaucoma
NCT05626491
Recruiting
The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your eye pressure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: Wills Eye Hospital, Philadelphia, Pennsylvania
Conditions: Glaucoma, Glaucoma, Open-Angle
Register for Updates
T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors
NCT05200559
Recruiting
Epithelial ovarian cancer (OC) is the most lethal gynecologic cancer: nearly 22,000 women are diagnosed with OC in the US annually and 63% are expected to die from their disease. The 5-year overall survival rate is unacceptably low at 20-30%, with \> 50% of patients experiencing recurrence of their disease. Recurrent, platinum-resistant OC is characterized by a low response to chemotherapy (\<10-15%) and poor prognosis, with overall survival estimated to be \<12 months. Thus, there is an urgent... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Epithelial Ovarian Cancer
Register for Updates
A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer
NCT06713564
Recruiting
The aim of this Phase 1b study is to investigate the safety and fluorescence signal of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by slow intravenous (IV) administration in patients undergoing surgical thoracoscopy and resection of lung cancer. Safety is the primary objective of this study, followed by the evaluation of the fluorescence signal as it relates to dose level and dosing time interval.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Lung Cancers
Register for Updates
STXBP1 and SYNGAP1 Related Disorders Natural History Study
NCT06555965
Recruiting
The purpose of this study is to find out more about STXBP1 and SYNGAP1 related disorders. The information gathered by this study will be used to prepare for clinical treatment trials. The primary objective of the study is to better define and outline the clinical spectrum of STXBP1 and SYNGAP1 through detailed developmental, seizure, and quality of life assessments as an extension of routine clinical care.
Gender:
ALL
Ages:
All
Trial Updated:
11/27/2024
Locations: The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Genetic Disease, STXBP1 Encephalopathy With Epilepsy, SYNGAP1-Related Intellectual Disability
Register for Updates
Skills Group for Youth At Clinical High-Risk for Psychosis
NCT05398120
Recruiting
This study is intended to test the feasibility of an integrated cognitive behavioral therapy (CBT) and dialectical behavioral therapy (DBT) skills group for adolescents and young adults at clinical high-risk (CHR) for psychosis. The current study applies a skills group drawing from evidence-based practices (e.g., cognitive behavioral therapy (CBT), dialectical behavioral therapy (DBT)) to those at CHR for psychosis. Up to 30 CHR individuals (starting with a minimum of 3 participants, N accounts... Read More
Gender:
ALL
Ages:
Between 13 years and 18 years
Trial Updated:
11/27/2024
Locations: Bellefield Towers, Pittsburgh, Pennsylvania
Conditions: Clinical High-Risk, Psychological
Register for Updates
Cardiac Sarcoidosis Randomized Trial
NCT03593759
Recruiting
Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hypothesize that low dose Prednisone(or Prednisolone)/Methotrexate combination will be as effective as standard dose Prednisone(or Prednisolone), and result in significantly better quality of life and less toxicity than sta... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Cardiac Sarcoidosis, Sarcoidosis
Register for Updates
Effect of a Wrist-worn Device That Produces a Small Vibration on Sleep and Performance That Can Occur During and After Night Shift Work
NCT06665672
Recruiting
The overarching goal of this research study is to determine "proof of concept" of effect of a non-invasive sleep aid device on sleep and performance during sleep opportunities (naps) that occur during and after simulated night shift work. Aim 1: To determine the effect of the ApolloNeuro device on sleep duration, sleep architecture, blood pressure, heart rate variability, and subjective ratings of sleep quality during and after simulated night shift work. Aim 2: To determine the effect of the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Sleep Duration, Psychomotor Performance
Register for Updates
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
NCT04414514
Recruiting
Investigators hypothesize that ruxolitinib 1.5% cream is an effective therapy for HS participants through inhibition of inflammatory activity. Investigators aim to: * Demonstrate the clinical efficacy of ruxolitinib 1.5% cream in decreasing the clinical disease activity after 16 weeks of treatment. * Investigate the impact of ruxolitinib 1.5% cream on skin inflammation through translational analyses of skin biopsy samples.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
11/26/2024
Locations: Penn State Hershey Medical Center, Hershey, Pennsylvania
Conditions: Hidradenitis Suppurativa
Register for Updates
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
NCT03588975
Recruiting
The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of patients aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
11/26/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Chondral Defect, Articular Cartilage Defect, Articular Cartilage Disorder of Knee, Osteochondritis Dissecans (OCD)
Register for Updates
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
NCT00775476
Recruiting
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack specificity and carry significant side-effects. We previously discovered the depletion of glutathione in lymphocytes of patients with SLE and associated this metabolic change with the elevation of the mitochondrial transmembrane potential. This study will titrate to tolerance during an initial 3 mo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: St. Luke's University Health Network, Allentown, Pennsylvania
Conditions: Systemic Lupus Erythematosus
Register for Updates